Board of Directors
Dr. Richard Afable
Dr. Afable has served as a director on the AcelRx board since 2013. Dr. Afable is the chief executive officer of St. Joseph Hoag Health, based in Irvine, California, a non-profit healthcare delivery system formed through the affiliation of Hoag Memorial Hospital Presbyterian and St. Joseph Health System in 2013. The network includes seven hospitals, an expansive physician network, and more than 50 outpatient and urgent care facilities in southern California. Dr. Afable's prior professional experience includes affiliations with managerial and patient oversight responsibility with Catholic Health East, Preferred Physician Partners, LLC, Catholic Healthcare Partners, and Wake Forest University Bowman Gray School of Medicine. He earned a Bachelor of Science in biology, a medical degree from Loyola University of Chicago, and a Master of Public Health from the University of Illinois at Chicago.
Vincent J. Angotti
Mr. Angotti brings over two decades of experience leading executive and commercial teams at public and private life sciences companies, most recently as CEO of XenoPort, Inc., a biopharmaceutical company focused on the development of treatments for neuropathic pain and other neurological disorders. During his tenure at XenoPort, Mr. Angotti was involved in the re-acquisition of Horizant from GSK and implemented a successful re-branding and re-launch strategy leading to XenoPort's acquisition by Arbor Pharmaceuticals, LLC in 2016. Previous to joining XenoPort, Mr. Angotti held senior sales and marketing positions at Reliant Pharmaceuticals, Inc. from 2001 – 2008. In his role as senior vice president of sales and marketing at Reliant, Mr. Angotti was integrally involved in the company's M&A discussions that concluded with Reliant's acquisition by GSK in 2007. Mr. Angotti began his career in the life sciences industry at Novartis Pharmaceuticals Corp., where he worked from 1991 – 2001 in sales and operations positions of increasing responsibility. Mr. Angotti earned a Bachelor of Science with a concentration in business management from Cornell University in 1990 and a Masters of Business Administration with honors in 2000 from Columbia University.
Ms. Bozilenko has over 30 years of investment banking and other healthcare industry experience, including raising more than $30 billion in capital and executing numerous M&A transactions. She currently serves as a strategic advisor to William Blair & Company, a firm she joined in 2010 as head of biotech & pharma and managing director. Prior to that, she worked at Bear, Stearns & Co. Inc. as a senior managing director in the healthcare group, at Bank of America Securities as a managing director and head of biotechnology, and at Vector Securities International, where she was a partner. Ms. Bozilenko was also a principal at Kidd & Company, a private-equity firm. She received her Bachelor of Arts in molecular biology and Master of Arts in economic history from the University of Chicago.
Mark G. Edwards
Mr. Edwards has served as a director on the AcelRx board since 2011. Mr. Edwards is managing director of Bioscience Advisors Inc., a biopharmaceutical consulting firm he founded in 2011. He also currently sits on the board of the California Institute for Biomedical Research (Calibr), based in La Jolla, CA. Previously, he was managing director and a principal of Deloitte Recap LLC, a wholly-owned subsidiary of Deloitte Touche Tohmatsu. Until its sale to Deloitte in 2008, Mr. Edwards was the managing director and founder of Recombinant Capital, Inc. (Recap), a consulting and database firm based in Walnut Creek, California. More than 100 biotechnology, pharmaceutical and service companies have retained Mr. Edwards to advise on biotech alliances and valuations over the past two decades. He has provided expert testimony in lawsuits involving reasonable royalties, transfer pricing and custom and practice in the biotechnology and pharmaceutical industries. Prior to founding Recap in 1988, Mr. Edwards was manager of business development at Chiron Corporation. He received his Bachelor of Arts and Master of Business Administration from Stanford University.
Stephen J. Hoffman, PhD, MD
Dr. Hoffman has served as a director on the AcelRx board since February 2010. Dr. Hoffman was the Chief Executive Officer, and Board member of Aerpio Pharmaceuticals from December 2017 to October 2019. Prior to Aerpio, Dr. Hoffman was a senior advisor to PDL BioPharma, Inc. since February of 2014. Prior to that, he served as a managing director at Skyline Ventures, a venture capital firm, from May 2007 until February of 2014. From January 2003 to March 2007, Dr. Hoffman was a general partner at TechnoVenture Management, a venture capital firm. Prior to that, he served as president, chief executive officer and a director of Allos Therapeutics, a biopharmaceutical company from 1994 to 2002, where he remained chairman of the board until its acquisition in 2012. From 1990 to 1994, Dr. Hoffman completed a fellowship in clinical oncology and a residency/fellowship in dermatology, both at the University of Colorado. Dr. Hoffman was the scientific founder of Somatogen Inc., a biotechnology company that was acquired in 1998 by Baxter International, Inc., a global medical products and services company, where he held the position of vice president of science and technology from 1987 until 1990. He serves on the board of directors of Concert Pharmaceuticals, Inc., a biotechnology company and Dicerna Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Hoffman holds a doctorate in bio-organic chemistry from Northwestern University and a medical degree from the University of Colorado School of Medicine.
Pamela P. Palmer, MD, PhD
Dr. Palmer has served as a director on the AcelRx board and the Company’s chief medical officer since she co-founded the company in July 2005. Dr. Palmer gained extensive experience in the treatment of pain during her tenure as the director of the UCSF Pain Center for Advanced Research and Education (PainCARE) from 2005 to 2009, during which time the American Pain Society named the UCSF Pain Management Center and PainCARE jointly as one of only six centers of excellence nationwide. Prior to PainCARE, from 1999 to 2005, she was medical director of the UCSF Pain Management Center, which uses a comprehensive and multidisciplinary approach to treat patients with various stages and types of complex acute and chronic pain. From 1996 to 1999, Dr. Palmer worked as a faculty member at UCSF, where she conducted research on basic science mechanisms of pain transmission in her NIH-funded laboratory. In 1994 she co-founded Omeros Corporation, a biopharmaceutical company developing small-molecule and protein therapeutics aimed at improving pain management and clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Dr. Palmer remains a consultant to Omeros. Dr. Palmer received a medical degree and a doctorate in neuroscience at Stanford University, and continued on to the University of California, San Francisco for her anesthesia residency. She has an undergraduate degree in electrical engineering. Dr. Palmer is certified in anesthesiology and pain medicine by the American Board of Anesthesiology.
Howard B. Rosen
Mr. Rosen has served on the AcelRx board since 2008 and as chief executive officer from 2015-17. Mr. Rosen brings more than 25 years of experience in pharmaceutical and biotechnology leadership and strategy to AcelRx. Previously, he was vice president, commercial strategy at Gilead Sciences, Inc. from 2004 to 2008, where his responsibilities included strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead's overall portfolio and business planning. Prior to joining Gilead, Mr. Rosen was president of ALZA Corporation where he was responsible for all aspects of managing ALZA as an independent 1000-person operating company within the Johnson & Johnson Family of Companies. Previously at ALZA as vice president, product development, he was responsible for product development activities, portfolio management and corporate and new product planning.
Mr. Wan has served as a director on the AcelRx board since August 2006. Mr. Wan is a founding managing director of Causeway Media Partners. He is also a founding general partner of Three Arch Partners. Prior to co-founding Three Arch Partners in 1993, Mr. Wan was a general partner at Brentwood Associates, a private equity firm. Mr. Wan holds a Bachelor of Science in engineering and a Bachelor of Arts in economics from Yale University and a Master of Business Administration from the Stanford Graduate School of Business.